Table 2 Clinical findings, AQP4-Ab status in serum and CSF, and median AQP4-Ab serum titres in the various disease groups.
Diagnosis | No of CSF samples | Acute attack at time of LP (%) | AQP4-Ab, serum (%) | AQP4-Ab, CSF (%) | Median serum titre (range; N) |
|---|---|---|---|---|---|
NMOSD | 45 | 29/40 (73) | 31/45 (69) | 21/45 (47) | 1000 (10-12500;26) |
   NMO | 26 | 16/22 (73) | 16/26 (62) | 11/26 (42) | 1000 (125-7000;12) |
   LETM | 8 | 6/8 (75) | 7/8 (88) | 5/8 (63) | 250 (62.5-12500;7) |
   ON | 11 | 7/10 (70) | 8/11 (73) | 5/11 (45) | 250 (10-7000;7) |
   Relapse | 29 | 29/29 (100) | 20/29 (69) | 17/29 (59) | 1000 (250-12500;20) |
   Remission | 11 | 0/11 (0) | 7/11 (64) | 1/11 (9) | 187.5 (10-250;6) |
   AQP4-Ab seropositive | 31 | 20/31 (65) | 31/31 (100) | 21/31 (68) | 1000 (10-12500;26) |
   AQP4-Ab seronegative | 14 | 9/14 (64) | 0/14 (0) | 0/14 (0) | Negative |
Controls | 42 | 31/38 (82) | 0/42 (0) | 0/42 (0) | Negative |
   MS | 28 | 22/28 (79) | 0/28 (0) | 0/28 (0) | Negative |
   OND | 14 | 9/10 (90)§ | 0/14 (0) | 0/14 (0) | Negative |